April 18, 2018 / 10:46 PM / in a month

BRIEF-Astrazeneca says U.S. FDA Approves Tagrisso As 1st-Line Treatment For EGFR-Mutated Non-Small Cell Lung Cancer

April 18 (Reuters) - AstraZeneca PLC:

* US FDA APPROVES TAGRISSO AS 1ST-LINE TREATMENT FOR EGFR-MUTATED NON-SMALL CELL LUNG CANCER Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below